期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 61, 期 9, 页码 -出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01117-17
关键词
extended-spectrum OXA; Pseudomonas aeruginosa; multidrug resistance; ceftolozane-tazobactam; ceftazidime-avibactam
资金
- Ministerio de Economia y Competitividad of Spain, Instituto de Salud Carlos III
- European Regional Development Fund ERDF, through Spanish Network for the Research in Infectious Diseases [RD12/0015/0006, RD15/0016/0004, PI15/00088]
Resistance development to novel cephalosporin-beta-lactamase inhibitor combinations during ceftazidime treatment of a surgical infection by Pseudomonas aeruginosa was investigated. Both initial (97C2) and final (98G1) isolates belonged to the high-risk clone sequence type (ST) 235 and were resistant to carbapenems (oprD), fluoroquinolones (GyrA-T83I, ParC-S87L), and aminoglycosides (aacA7/aacA8/aadA6). 98G1 also showed resistance to ceftazidime, ceftazidime-avibactam, and ceftolozane-tazobactam. Sequencing identified bla(OXA-2) in 97C2, but 98G1 contained a 3-bp insertion leading to the duplication of the key residue D149 (designated OXA-539). Evaluation of PAO1 transformants producing cloned OXA-2 or OXA-539 confirmed that D149 duplication was the cause of resistance. Active surveillance of the emergence of resistance to these new valuable agents is warranted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据